BRIEF—Neurimmune collaborates with Ono Pharma

Swiss biotech Neurimmune has entered into a collaboration with Japan’s Ono Pharmaceutical focused on the development of human antibodies against a novel therapeutic target for neurodegenerative diseases.

Under the terms of the accord, Neurimmune will conduct research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational Medicine (RTM) technology platform, while Ono will be exclusively responsible for worldwide development and marketing of products.

Neurimmune will receive an upfront payment, research fees, success-based milestones on the research and development progress, as well as royalties on product sales.

Jan Grimm, chief scientific officer and co-founder of Neurimmune, said: "This new collaboration serves our commitment to patients to fully leverage our RTM technology for the discovery and development of breakthrough medicines in areas of high unmet medical need."